Summary
Fidelity Select Biotechnology Pt is a mutual fund run by Fidelity. It does not trade on an exchange: you buy it from the fund company at a price set once a day. Positions inside: 227. The ten largest make up 44% of the fund.
- Positions
- 227
- Dividend yield
- 5.53%
- Running since
- 1985
What speaks for it
- Average yearly growth over the last ten years: 5.7%.
- It has been running since 1985.
What to watch
- 100% of the fund is in one sector (Healthcare).
- 84% of the fund is in one country (United States).
- In the last five years its price once dropped by 55% from its high.
A fund has no Bulios Score and no Fair Price of its own - both are computed from the results of a single company. This page shows what is inside the fund and what it costs instead.
Price
Performance
- 1 month
- +1.5%
- 3 months
- +4.2%
- This year
- +16%
- 1 year
- +22%
- 3 years
- +101%
- 5 years
- +33%
- 10 years
- +75%
- Avg. market cap
- $102.8B
- P/E
- 31.3x
- Forward P/E
- -
- P/S
- 10.6x
- P/B
- 7.4x
- P/FCF
- 29.9x
- EV/EBITDA
- 24.3x
- Dividend yield
- 0.51%
- ROIC
- -10.8%
- ROE
- -22.4%
- Gross margin
- -380.2%
- Operating margin
- -2,813.9%
- Net margin
- -2,251.7%
- Payout ratio
- 16.1%
- Net debt/EBITDA
- 6.7x
- Beta
- 0.70
Weighted average of the 50 largest companies, which make up 79% of the fund. Banks and insurers are left out of the gross margin, the ROIC and the EBITDA figures.
What is inside?
Moderately concentrated- 1 ABAbbVie ABBV 10%
- 2 KRKrystal Biotech KRYS 10%
- 3 AMAmgen AMGN 7.0%
- 4 MRModerna MRNA 3.5%
- 5 INInsmed INSM 2.4%
- 6 RVRevolution Medicines RVMD 2.4%
- 7 ARArgenx ARGX 2.3%
- 8 PRPraxis Precision Medicines, Inc. PRAX 2.3%
- 9 ASAscendis Pharma ASND 2.0%
- 10 NTNatera NTRA 1.7%
Positions in the fund: 227. The ten largest make up 44% of it.
Composition as of Oct 24, 2026.
Where is it spread?
One sector dominatesBy sector
- Healthcare 100%
By country
- United States 84%
- Netherlands 2.8%
- Denmark 2.6%
- United Kingdom 2.5%
- Other countries 8.4%
By company size
- Mega cap 18%
- Large cap 27%
- Mid cap 41%
- Small cap 14%
- Micro cap 0.6%
By the company's market value: Mega cap from $200B, Large cap from $10B, Mid cap from $2B, Small cap from $300M, Micro cap below $300M.
Largest sector: Healthcare (100%). Largest country: United States (84%). Largest size group: Mid cap (41%).
What does it cost me?
We do not know the costs of this fund.
How has it done?
Growing over the long run- A year on average, 10 years
- +5.7%
- Deepest drop
- -55%
- Yearly volatility
- 25%
Average yearly growth over the last ten years: 5.7%. Deepest drop in these years: 55% below the earlier high.
Does it pay dividends?
Yes, it pays out- Yield
- 5.53%
- Payments a year
- 2
- Last payment
- $1.06
Over the last 12 months it paid $1.62 per share, which is 5.53% of today's price. The last payment was $1.06 on Apr 10, 2026.
How expensive are the companies inside?
Rather expensive- P/E of the companies inside
- 31.3
- Average Bulios Score
- 50 out of 100
Weight by Bulios Fair Price
- Undervalued 9.4%
- Fairly valued 5.7%
- Overvalued 85%
On average the companies inside trade for 31.3 times their yearly profit. By Fair Price, 85% of the rated weight comes out as overvalued.
Counted from its largest companies (50), which make up 79% of the fund. Each company counts by its weight. We use the metrics, the Bulios Score and the Fair Price of the companies themselves.
Can I buy it as an ETF?
A mutual fund is bought from the fund company. These ETFs hold much of the same and trade on an exchange, so an ordinary broker carries them.
| Fund | Domicile | Size | 1-year change | Dividends | ||
|---|---|---|---|---|---|---|
TD TDNA T. Rowe Price Biotech ETF | United States | 0.55% | $9.51M | - | - | 43% |
CU CURE.AX Global X - S&P Biotech ETF | Australia | 0.45% | $27.3M | +32% | Reinvests | 43% |
XB XBI SPDR S&P Biotech ETF | United States | 0.35% | $7.82B | +40% | Pays out | 43% |
2B 2B70.DE iShares Nasdaq US Biotechnology UCITS ETF | Ireland | 0.35% | $926.0M | +41% | Reinvests | 41% |
IB IBB iShares Biotechnology ETF | United States | 0.44% | $10.8B | +37% | Pays out | 41% |
IB IBBQ Invesco Nasdaq Biotechnology ETF | United States | 0.19% | $81.8M | +35% | Pays out | 40% |
